Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc KNBIF


Primary Symbol: V.KNE

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by KevinOlearyon Jun 29, 2024 5:48pm
53 Views
Post# 36112303

RE:RE:RE:New Press Release - Kane Biotech Makes First Commercial Sale of revyve(TM) Antimicrobial Wound Gel to ProgenaCare Global

RE:RE:RE:New Press Release - Kane Biotech Makes First Commercial Sale of revyve(TM) Antimicrobial Wound Gel to ProgenaCare GlobalThe timelines for dispersin trials are determined 100% by the FDA. kne just tried to estimate when the trials would start, but it's a mug's game. The FDA is a massive bureaucracy, and doesn't know much about biofilms. The pre-application meetings are widely spaced apart and you don't get to talk to people who will give you a nice blueprint of how to submit an application for something this complex. Instead, you are stuck dealing with people who try to help but have limited data and understanding. 

When you say the company doesn't meet timelines, you mean dealing with the FDA is vague and time consuming. All a company can do is guess how much fiddling the FDA will do. Look at the Revyve approval that took so long. There isn't even a labelling claim for Revyve, yet it took 6 months after applying to get approved for a "hydrogel." That's all the claim is on the tube, "hydrogel." That doesn't include the many months of pre-application meetings.

<< Previous
Bullboard Posts
Next >>